NCT02373215View on ClinicalTrials.gov

Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Uremic Pruritus
Interventions
DRUG

Nalbuphine HCL ER

Nalbuphine HCL extended release tablet

Sponsors

Lead Sponsor

Trevi Therapeutics

Collaborators (1)

Davita Clinical Research
All Listed Sponsors
collaborator

Davita Clinical Research

INDUSTRY

lead

Trevi Therapeutics

INDUSTRY